The Manufacturers Life Insurance Company Acquires 14,766 Shares of Boston Scientific Corporation $BSX

Key Points

• The Manufacturers Life Insurance Company increased its stake in Boston Scientific by 1.3%, owning 1,184,915 shares valued at approximately $119.53 million.
• Institutional investors and hedge funds own 89.07% of Boston Scientific's stock, indicating strong institutional interest in the company.
• Boston Scientific reported strong quarterly earnings of $0.75 EPS, surpassing the consensus estimate of $0.72, with a year-over-year revenue increase of 22.8%.

The Manufacturers Life Insurance Company increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,184,915 shares of the medical equipment provider's stock after acquiring an additional 14,766 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of Boston Scientific worth $119,534,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of BSX. Colonial Trust Co SC boosted its position in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter worth approximately $27,000. Finally, Ameriflex Group Inc. purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $31,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Truist Financial lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Oppenheimer lifted their price target on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research note on Thursday, July 24th. Robert W. Baird lifted their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Barclays lifted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, UBS Group lifted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Trading Up 0.5%

NYSE:BSX traded up $0.52 during trading hours on Thursday, hitting $108.05. The company had a trading volume of 2,722,070 shares, compared to its average volume of 7,456,434. The company has a market capitalization of $160.10 billion, a PE ratio of 64.26, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The stock has a 50-day moving average price of $104.71 and a 200 day moving average price of $102.18. Boston Scientific Corporation has a 52 week low of $80.50 and a 52 week high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.